Should I Buy ARTL? ARTL 2026 Analysis

Should You Buy Artelo Biosciences Inc (ARTL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.470

1 Day change

7.30%

52 Week Range

28.600

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: there are no Intellectia buy signals (AI Stock Picker and SwingMax both show no signal), and price action is still weak near support.
Best case near-term setup is a small mean-reversion bounce from oversold levels, but there isn’t a high-conviction trigger to justify chasing an entry pre-market.
With earnings on 2026-03-02 (pre-market) and no recent news/catalysts, the risk/reward for an impatient buyer is unattractive until the stock reclaims key levels (around the 1.70 pivot) with improving momentum.

Technical Analysis

Trend/Momentum: MACD histogram is slightly positive (0.00629) but contracting, suggesting fading upside momentum rather than a fresh uptrend.
RSI (6): 29.26, which is near oversold, consistent with a stretched downside move and potential for a short-lived bounce.
Moving averages: Converging MAs = no clear trend; market is in a low-conviction chop/down phase.
Key levels: Pre-market price ~1.53 is below S1 (1.553) and above S2 (1.463); that places ARTL in a fragile zone where a breakdown to S2 is plausible. Upside resistance sits near Pivot 1.698, then R1 1.843.
Pattern-based forward view: Similar-pattern stats imply ~50% chance of -0.49% next day, but mild positive drift over 1 week (+1.48%) and 1 month (+4.54%)—not strong enough to override current weakness.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- RSI near oversold may support a technical bounce if selling pressure exhausts near 1.46–1.55 support.
- Historical pattern projection shows modestly positive 1-week and 1-month drift (not a strong edge, but supportive if price stabilizes).
- Net loss and EPS improved YoY in the latest reported quarter (cost control/expense timing may be helping).

Neutral/Negative Catalysts

- No Intellectia buy signals (AI Stock Picker/SwingMax), reducing confidence for an immediate entry.
- Price is trading below S1 and below the pivot (1.698), indicating the stock is still technically weak.
- No recent news or identified event-driven catalyst to re-rate the stock in the immediate term.
- Micro-cap profile (market cap shown as ~$3.31M) typically implies thin liquidity and higher execution risk, which is unfavorable for impatient entries.
- Upcoming earnings (2026-03-02 pre-market) can create sharp moves without advance notice from news flow.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: 0 (no operating revenue; unchanged YoY).
Net income: -$3.12M (improved YoY per dataset, but still a sizeable loss).
EPS: -3.96 (improved YoY, still deeply negative).
Overall: improving losses, but the company remains pre-revenue and unprofitable, so price tends to be catalyst-dependent rather than fundamentals-driven.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price-target change data was provided, so there is no clear Wall Street consensus trend to lean on.
Practical pro view (in absence of coverage): potential optionality typical of development-stage biotech.
Practical con view: lack of revenue and continuing losses mean the stock often needs clear clinical/business catalysts to sustain upside—none are visible in the provided data.

Analyst Rating

Wall Street analysts forecast ARTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTL is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.370

Low

Averages

High

Current: 1.370

Low

Averages

High

D. Boral Capital

Jason Kolbert

Buy

Hold

downgrade

AI Analysis

2025-09-08

Reason

D. Boral Capital

Jason Kolbert

Price Target

AI Analysis

2025-09-08

downgrade

Buy

Hold

Reason

D. Boral Capital analyst Jason Kolbert downgraded Artelo Biosciences to Hold from Buy and removed the firm's prior price target following the company's "unexpected" $3M capital raise last week that came after what appeared to be an unsuccessful crypto-related strategy. Repeated attempts to reach management for clarification have been unsuccessful, notes the analyst, who cites the combination of "poor communication, a confusing strategic direction, and a dilutive capital raise" for the firm's more cautious stance.

D. Boral Capital

Hold

Buy

upgrade

$20

2025-07-08

Reason

D. Boral Capital

Price Target

$20

2025-07-08

upgrade

Hold

Buy

Reason

D. Boral Capital upgraded Artelo Biosciences (ARTL) to Buy from Hold with a $20 price target. The firm, which has adjusted its model and raised assumptions for the now completed reverse split, continues to view Artelo as an emerging biotechnology company focused on Cachexia and Chemotherapy-induced peripheral neuropathy with the lead program ART27.13, a Phase 2 asset acquired from Astra-Zenca (AZN), the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARTL

Unlock Now

ARTL Should I Buy

ARTL Should I Buy

Should You Buy Artelo Biosciences Inc (ARTL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch